NCT04947189View on ClinicalTrials.gov

Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2027

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

Seviteronel-D (Seivteronel in combination with dexamethasone)

Use of Seviteronel-D (Serivteronel and dexamethasone) in the treatment of androgen receptor positive solid tumours.

DRUG

Docetaxel

Use of docetaxel chemotherapy for solid tumours

Trial Locations (1)

2010

RECRUITING

Kinghorn Cancer Centre, Darlinghurst

All Listed Sponsors
lead

St Vincent's Hospital, Sydney

OTHER